PCA
MYGN icon

Pallas Capital Advisors’s Myriad Genetics MYGN Stock Holding History

Pallas Capital Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.9K Buy
+12,067
New +$54.8K ﹤0.01% 975
2026
Q1 		– Sell
-12,924
Closed -$79.5K – 940
2025
Q4 		$79.5K Buy
+12,924
New +$93.7K ﹤0.01% 852
2025
Q3 		– Sell
-10,808
Closed -$57.4K – 932
2025
Q2 		$57.4K Buy
+10,808
New +$63.8K ﹤0.01% 818

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Pallas Capital Advisors's MYGN Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in Myriad Genetics (MYGN) in Q2 2026: 12,067 shares worth $68.9K. The stake represents ﹤0.01% of the portfolio and ranks #975 among its holdings. This is a return to the name: Pallas Capital Advisors previously reported a position in MYGN as recently as Q4 2025.

Pallas Capital Advisors first reported a position in MYGN in Q2 2025 and has held it in 3 quarters since. The position peaked at $79.5K in Q4 2025. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Pallas Capital Advisors held 12,067 shares of Myriad Genetics worth $68.9K as of Q2 2026.
  • Myriad Genetics was a new Pallas Capital Advisors position in Q2 2026.
  • Myriad Genetics made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #975 holding.
  • Pallas Capital Advisors first reported a position in Myriad Genetics in Q2 2025 and has held it in 3 quarters since.
  • Pallas Capital Advisors's Myriad Genetics position peaked at $79.5K in Q4 2025.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.